Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac's Q3 Pretax Loss Widens, Revenue Rises

11/19/2021 | 03:41am EST


ę MT Newswires 2021
All news about CUREVAC N.V.
01/18CUREVAC N : Chief Technology Officer to Pursue New Career outside Biotech Industry - Form ..
PU
01/18JMP Securities Starts CureVac at Market Outperform With $52 Price Target
MT
01/18CureVac Technology Chief Mariola Fotin-Mleczek to Step Down
MT
01/17CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
EQ
01/17CureVac Announces Resignation of Mariola Fotin-Mleczek as Chief Technology Officer
CI
01/13CUREVAC N : In relation to the Parties' share portfolios in CureVac N.V. (NL-Amsterdam) - ..
PU
01/03CUREVAC N : Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as..
PU
2021CureVac Stock Slips Following Kempen's Stock Rating Downgrade
MT
2021Kempen Downgrades CureVac to Sell From Neutral, Adjusts Price Target to $20 From $50
MT
2021CUREVAC N.V.(NASDAQGM : CVAC) added to NASDAQ Biotechnology Index
CI
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2021 0,00 M 0,00 M 0,00 M
Net income 2021 -458 M -518 M -518 M
Net cash 2021 976 M 1 104 M 1 104 M
P/E ratio 2021 -7,96x
Yield 2021 -
Capitalization 4 037 M 4 579 M 4 569 M
EV / Sales 2021 102 047 729x
EV / Sales 2022 13,8x
Nbr of Employees 505
Free-Float 44,9%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 19,81 €
Average target price 44,66 €
Spread / Average Target 125%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean StÚphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-34.51%4 579
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
ICON PUBLIC LIMITED COMPANY-17.00%20 923